temozolomide has been researched along with Anal Cancer in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide was administered orally once per day at a dosage of 200 mg/m2/d for five consecutive days about every 4 weeks." | 5.56 | Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports. ( Cao, F; Chen, S; Fan, W; Li, D; Ma, W; Qi, H; Shen, L; Song, Z; Wen, X; Wu, Y; Xie, L; Zhang, X, 2020) |
| "Temozolomide was administered orally once per day at a dosage of 200 mg/m2/d for five consecutive days about every 4 weeks." | 1.56 | Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports. ( Cao, F; Chen, S; Fan, W; Li, D; Ma, W; Qi, H; Shen, L; Song, Z; Wen, X; Wu, Y; Xie, L; Zhang, X, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S | 1 |
| Zhang, X | 1 |
| Shen, L | 1 |
| Qi, H | 1 |
| Ma, W | 1 |
| Cao, F | 1 |
| Xie, L | 1 |
| Song, Z | 1 |
| Wu, Y | 1 |
| Li, D | 1 |
| Wen, X | 1 |
| Fan, W | 1 |
| Quintás-Cardama, A | 1 |
| Lazar, AJ | 1 |
| Woodman, SE | 1 |
| Kim, K | 1 |
| Ross, M | 1 |
| Hwu, P | 1 |
2 other studies available for temozolomide and Anal Cancer
| Article | Year |
|---|---|
Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; | 2008 |